tbuckley/cabot-search huggingface dataset:
Abstract 19052: Interferon B1A-Induced Dilated Cardiomyopathy
Authors: Michael DiCaro, Scott Turnbull, Ala Abdallah, KaChon Lei, Chowdhury H Ahsan
Journal: Circulation (2023)

Introduction: Congestive heart failure is a leading causes of morbidity and mortality. Interferon therapy is a rare cause of dilated cardiomyopathy (DCM) and Heart Failure with Reduced Ejection Fraction (HFrEF). Specifically, interferon Alpha has been associated with cardiotoxicity. Here we describe a case of interferon B1A - induced HFrEF and DCM in a patient who took subcutaneous Interferon B1A for 11 years before developing clinical signs of heart failure. To our knowledge, only four other cases have been reported. Case Description: A 70-year-old man with a history of multiple sclerosis managed with Interferon B1A presented with shortness of breath, orthopnea, and lower extremity edema for 10 days. Physical examination revealed jugular venous distension and pitting edema. Brain natriuretic peptide (BNP) was 1580 pg/mL, troponin was 49 ng/L. Lipid panel, complete blood count, complete metabolic panel, Hemoglobin A1c, and thyroid stimulating hormone were within normal limits. Urine drug screen was negative. Chest X-ray revealed pulmonary vascular congestion and small pleural effusions bilaterally. A Transthoracic echocardiogram revealed mild aortic root dilatation (4.1cm), significant four-chamber dilatation, severely reduced left ventricular (LV) systolic function with an estimated ejection fraction of 20%, diastolic LV dysfunction, and moderately reduced systolic RV function, consistent with HFrEF and DCM (LVIDD 6.1cm). Coronary angiography showed normal coronary anatomy. The patient was started on guideline-directed medical therapy for HFrEF. Close follow-up was arranged to track improvement in systolic function after cessation of interferon b1a and consideration for Cardiac MRI and possible RV biopsy to evaluate for other causes of cardiomyopathy. Discussion/Conclusions: Due to the patient’s negative ischemic workup and absence of risk factors for cardiovascular disease, we strongly suspect that the patient’s cardiomyopathy was due to interferon B1A. With only 4 other cases of interferon B1A-induced DCM reported, it is a rare cause of medication-induced DCM. Interferon B1A should be considered a potential risk factor for developing heart failure, especially in high-risk patients.
Abstract 14555: Early Predictors That Identify Patients With Significant Left Main and Three-Vessel Coronary Artery Disease in Non-ST Elevation Acute Coronary Syndrome: Validating the MADISON Score
Authors: Rayan Jo Rachwan, Omar Chehab, Rody Bou Chaaya, Furqan Rajput, Aneeq Waqar, Fauzia Osman, Andreas De Biasi, Satoru Osaki, Ruben A Alexanian, Gregory Tester, David Lewis, Giorgio Gimelli, Kurt Jacobson, Neal S Kleiman, Amish N Raval
Journal: Circulation (2023)

Introduction: In patients with non-ST elevation acute coronary syndrome (NSTE-ACS), identifying those with a high probability of having high-risk disease such as left main (LM) or three-vessel disease (3VD) could influence decisions to preload with P2Y12 inhibitors and timing of coronary angiography. The MADISON score was developed to predict LM/3VD on coronary angiography in patients with NSTE-ACS. In this study, we validated the MADISON score using data from an external cohort. Methods: The MADISON score was first developed using a retrospective cohort of 1700 patients presenting with NSTE-ACS at the University of Wisconsin-Madison (UW) (2011-2018). Those with prior CABG, cardiac arrest/shock, and bleeding on initial presentation were excluded from the analysis. Multivariable estimates were employed and model performance was assessed using receiver operating characteristic curve analysis. The score was then validated using a retrospective Houston Methodist Hospital (HMH) cohort of 622 patients (2019-2022). Results: The MADISON score variables and their adjusted odds ratios (95% CI) are presented in Figure 1A. Risk categories and corresponding LM/3VD probabilities are presented in Figure 1B. In the UW cohort, the area under the curve (AUC) was 0.68 (0.65-0.71) (Figure 2A). Interestingly, the AUC was also 0.68 (0.64-0.72) in the HMH validation cohort (Figure 2B). Conclusions: The MADISON score performed well and similarly between 2 large, independent cohorts in predicting patients most likely to have LM/3VD. The MADISON score is a simple and practical tool to guide decisions. Prospective validation of the score is planned to evaluate its impact on clinical outcomes.
Harnessing two-dimensional nanomaterials for diagnosis and therapy in neurodegenerative diseases: Advances, challenges and prospects
Authors: Samir Kumar Beura, Abhishek Ramachandra Panigrahi, Pooja Yadav, Irene Palacio, Elena Casero, Carmen Quintana, Jyoti Singh, Manoj Kumar Singh, Jose A. Martín Gago, Sunil Kumar Singh
Journal: Ageing Research Reviews (2024)
LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM
Authors: Zehua Bian, Fan Yang, Peiwen Xu, Ge Gao, Chunyu Yang, Yulin Cao, Surui Yao, Xue Wang, Yuan Yin, Bojian Fei, Zhaohui Huang
Journal: Molecular Cancer (2024)

Abstract Background Colorectal cancer (CRC) is a major cause of cancer-related deaths worldwide, and chemoresistance is a major obstacle in its treatment. Despite advances in therapy, the molecular mechanism underlying chemoresistance in CRC is not fully understood. Recent studies have implicated the key roles of long noncoding RNAs (lncRNAs) in the regulation of CRC chemoresistance. Methods In this study, we investigated the role of the lncRNA LINC01852 in CRC chemoresistance. LINC01852 expression was evaluated in multiple CRC cohorts using quantitative reverse transcription PCR. We conducted in vitro and in vivo functional experiments using cell culture and mouse models. RNA pull-down, RNA immunoprecipitation, chromatin immunoprecipitation, and dual luciferase assays were used to investigate the molecular mechanism of LINC01852 in CRC. Results Our findings revealed that a lncRNA with tumor-inhibiting properties, LINC01852, was downregulated in CRC and inhibited cell proliferation and chemoresistance both in vitro and in vivo. Further mechanistic investigations revealed that LINC01852 increases TRIM72-mediated ubiquitination and degradation of SRSF5, inhibiting SRSF5-mediated alternative splicing of PKM and thereby decreasing the production of PKM2. Overexpression of LINC01852 induces a metabolic switch from aerobic glycolysis to oxidative phosphorylation, which attenuates the chemoresistance of CRC cells by inhibiting PKM2-mediated glycolysis. Conclusions Our results demonstrate that LINC01852 plays an important role in repressing CRC malignancy and chemoresistance by regulating SRSF5-mediated alternative splicing of PKM, and that targeting the LINC01852/TRIM72/SRSF5/PKM2 signaling axis may represent a potential therapeutic strategy for CRC.
A valuable glioblastoma prognostic marker driven by radiosensitivity
Authors: James Randall, Sean Sachdev
Journal: Neuro-Oncology (2024)

Journal Article A valuable glioblastoma prognostic marker driven by radiosensitivity Get access James Randall, James Randall Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Sean Sachdev Sean Sachdev Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA Corresponding Author: Sean Sachdev, MD, Department of Radiation Oncology, Northwestern University Robert H. Lurie Comprehensive Cancer Center, 676 N St. Clair, Arkes Pavilion, Suite 1820, Chicago, IL 60611, USA (sean.sachdev@northwestern.edu). https://orcid.org/0000-0001-7682-9673 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 26, Issue 3, March 2024, Pages 514–515, https://doi.org/10.1093/neuonc/noad266 Published: 23 January 2024 Article history Published: 23 January 2024 Corrected and typeset: 30 January 2024
Novel traction device for endoscopic submucosal dissection: a rotatable transparent cap, an additional channel, and a traction wire
Authors: Xi Chen, Zhenqun Lin, Xiangqing Li, Xiaoning Yang, Wenjuan Liu, Zehui Huang, Shuntian Cai
Journal: Endoscopy (2024)

Traditionally, endoscopic procedures have been limited to a single–channel device, making it difficult for endoscopists to perform endoscopic submucosal dissection (ESD). As a result, several solutions have been developed, each with its own advantages and disadvantages, including traction devices [1] [2], double-channel endoscopes [3], laparoscopy–endoscopy combined surgery [4], and surgical endoscopic robots [5]. To address these challenges, we fabricated a rotatable transparent cap with a fixed channel that can accommodate endoscopic surgical instruments.
Life-threatening small-bowel diverticular bleed treated by double-balloon enteroscopy in a patient refusing transfusion
Authors: Laura A. Lucaciu, Alexandros Skamnelos, Alberto Murino, Nikolaos Lazaridis, Rocio Chacchi Cahuin, Regina Raymond, Edward J. Despott
Journal: Endoscopy (2024)

Double-balloon enteroscopy (DBE) is the gold standard for minimally invasive investigation and management of a vast array of small-bowel pathology [1]. Small-bowel diverticulosis is rare, with a prevalence of 1%–2% in the general population [2]. Complications including diverticular bleeding, perforation, and obstruction may occur in 10%–30% of cases [2] [3]. We present a case of massive jejunal diverticular bleed successfully managed by DBE-facilitated endotherapy.
Endoscopic submucosal dissection-assistance robot: a miniature surgical manipulator for endoscopic submucosal dissection
Authors: Yaxian Kuai, Jie Peng, Jing Jin, Aijiu Wu, Derun Kong
Journal: Endoscopy (2024)

One-handed operation and gravity-induced blind dissection are technical difficulties in endoscopic submucosal dissection (ESD) procedures [1]. In order to reduce the difficulty of the procedure and minimize the risk of perforation and bleeding, we have developed a microsurgical manipulator, the ESD-assistance robot, which provides a "second hand" with auxiliary traction, clamping, and fixation functions during procedures.
Atypical esophageal submucosal tumor lesion with aortoesophageal fistula after thoracic endovascular aortic repair
Authors: Koichi Soga
Journal: Endoscopy (2024)

Aortoesophageal fistula (AEF) is a rare but lethal entity that is difficult to diagnose [1]. Despite the promising efficacy of thoracic endovascular aortic repair (TEVAR), which promotes the clinical use of this procedure, the incidence of AEF after TEVAR (post-TEVAR AEF) has increased, making it a major complication [2].
Endoscopic management of hepaticojejunal anastomosis fistula after Whipple’s resection
Authors: Oleg Dovbenko, Oleg Herasymenko
Journal: Endoscopy (2024)

A 49-year-old man with adenocarcinoma of the pancreatic head underwent a Whipple's resection 2 months ago. Reoperation for a subsequent leak from the hepaticojejunal anastomosis (HJA) was attempted, but failed. The external fistula from the anastomosis progressed. Fistulography detected leakage of contrast (20 × 10 cm) around the HJA, with an anastomotic defect of up to 1 cm. The patient suffered from weakness and hyperthermia up to 38°С. Conservative management failed. The drainage volume of enteral secretions with bile increased to 800 mL.
Black esophagus: complete esophageal necrosis with lower esophageal perforation
Authors: Lucile Héroin, Pierre-Yves Christmann, François Habersetzer, Pierre Mayer
Journal: Endoscopy (2024)

Black esophagus or acute esophageal necrosis is a rare condition, mainly reported as case reports in the literature [1]. Its pathogenesis seems to be multifactorial, with ischemia appearing to be the most common etiology in patients with cardiovascular risk factors and chronic medical conditions [2]. Diagnosis can be suggested by computed tomography (CT) findings but is based on upper gastrointestinal endoscopy. Mortality is high (30%). Treatment is conservative in most cases (75.4%), but endoscopic or surgical interventions can be required (25.6%) [3].
Reopenable-clip over-the-line method used inside a submucosal pocket during rectal endoscopic submucosal dissection for a full-thickness defect
Authors: Tatsuma Nomura, Shinya Sugimoto, Ryutaro Matsushima, Taishi Temma, Jun Oyamada, Keiichi Ito, Akira Kamei
Journal: Endoscopy (2024)

Colorectal endoscopic submucosal dissection (ESD) is a feasible method for en bloc resection of large tumors; however, en bloc resection of Paris type 0-Is lesions may require muscle layer dissection resulting in intraoperative perforation [1]. We previously reported a "reopenable-clip over-the-line method inside a submucosal pocket" (ROLM-SP) that allows closure of large full-thickness defects in the third space [2]. Here, we describe the first use of ROLM-SP for early rectal cancer ([Video 1]).
Hybrid argon pasma coagulation-assisted mucosal ablation in the management of refractory gastroesophageal reflux disease
Authors: Yun Bao, Silin Huang, Qiuping Qiu, Suhuan Liao, Xiaoping Hong, Miao He, Weiguang Qiao
Journal: Endoscopy (2024)

A 59-year-old woman was admitted to our hospital for the management of refractory gastroesophageal reflux disease (GERD). Gastroscopy, ascertaining the presence of GERD, revealed a manifestation classified as LA-C, accompanied by a conspicuous abnormality in the gastroesophageal flap valve, graded as Type III ([Fig. 1]). Dynamic reflux monitoring unveiled an acid exposure time of 32%, accompanied by a DeMeester score of 144.9.
Novel adjustable traction “noose knot” method for colorectal endoscopic submucosal dissection
Authors: Junki Tokura, Daisuke Ide, Keigo Suzuki, Chihiro Yasue, Akiko Chino, Masahiro Igarashi, Shoichi Saito
Journal: Endoscopy (2024)

Traction techniques effectively aid in endoscopic submucosal dissection (ESD) by maintaining satisfactory traction during dissection [1]. We previously reported the usefulness of the pocket creation method using a traction device (PCM with TD) for colorectal ESD [2] [3]. PCM with TD achieves stable en bloc resection and R0 dissection rates without adverse events. However, a single device may not provide sufficient traction, particularly in cases involving large lesions or a high degree of fibrosis. In these cases, additional traction is required, which increases the procedure difficulty. There are few previous reports on traction devices with adjustable traction force [4]. Herein, we present a novel traction device that enables adjustable traction through a method of ligating nylon threads, known as a "noose knot" ([Fig. 1]).
A new treatment for blown-out myotomy, a diverticulum formed after peroral endoscopic myotomy
Authors: Hiroya Sakaguchi, Shinwa Tanaka, Hirofumi Abe, Douglas Motomura, Hitomi Hori, Takashi Toyonaga, Yuzo Kodama
Journal: Endoscopy (2024)

Blown-out myotomy (BOM) is a potential postoperative complication for achalasia patients after both surgical and peroral endoscopic myotomy (POEM). It causes diverticular-like changes and food retention in the lower esophagus due to residual contraction and impaired discharge of esophageal contents. It occurs in 17.8% of patients after POEM and can be symptomatic [1]; however, no effective treatment for patients with symptomatic BOM has been reported.
Endoscopic ultrasound-guided ileocolostomy using a novel lumen-apposing metal stent for small-bowel obstruction with peritoneal carcinomatosis
Authors: Kyong Joo Lee, Se Woo Park, Dong Hee Koh, Jin Lee
Journal: Endoscopy (2024)

Peritoneal carcinomatosis is a serious condition stemming primarily from advanced gastrointestinal cancers, which causes significant symptoms such as vomiting due to malignant bowel obstruction (MBO) [1] [2]. The prognosis is poor, treatments often lack evidence-based guidelines, and many interventions, including surgical options for related MBO, present challenges [3]. Herein, we present a case of endoscopic ultrasound (EUS)-guided ileocolostomy using a novel lumen-apposing metal stent (LAMS) to treat MBO associated with peritoneal carcinomatosis.
Endoscopic submucosal dissection for hypopharynx lymphoepithelioma-like carcinoma
Authors: Cheng Guo, Bensong Duan, Li Zhang, Meidong Xu, Haibin Zhang
Journal: Endoscopy (2024)

A 48-year-old man with no significant medical history presented to our hospital with a 1-year history of a foreign body sensation in the pharynx. Upper endoscopy revealed a mass originating from the left aryepiglottic fold, which completely filled the pyriform sinus and partially obstructed the entrance to the esophagus ([Fig. 1] a). Ultrasound endoscopy revealed a well-demarcated hypoechoic mass with uniform echogenicity, which was chiefly located in the left aryepiglottic fold ([Fig. 1] b). With a diagnosis of giant inflammatory fibroma suspected, endoscopic submucosal dissection (ESD) was performed to prevent incarcerated obstruction ([Fig. 1] c,d, [Video 1]). Histological results confirmed the mass to be lymphoepithelioma-like carcinoma (LELC) ([Fig. 2]). The patient subsequently attended for follow-up endoscopy after a year, during which no evidence of recurrence or complications such as stenosis was seen.
Associations of Organophosphate Ester Flame Retardant Exposures during Pregnancy with Gestational Duration and Fetal Growth: The Environmental influences on Child Health Outcomes (ECHO) Program
Authors: Jiwon Oh, Jessie P. Buckley, Xuan Li, Kennedy K. Gachigi, Kurunthachalam Kannan, Wenjie Lyu, Jennifer L. Ames, Emily S. Barrett, Theresa M. Bastain, Carrie V. Breton, Claudia Buss, Lisa A. Croen, Anne L. Dunlop, Assiamira Ferrara, Akhgar Ghassabian, Julie B. Herbstman, Ixel Hernandez-Castro, Irva Hertz-Picciotto, Linda G. Kahn, Margaret R. Karagas, Jordan R. Kuiper, Cindy T. McEvoy, John D. Meeker, Rachel Morello-Frosch, Amy M. Padula, Megan E. Romano, Sheela Sathyanarayana, Susan Schantz, Rebecca J. Schmidt, Hyagriv Simhan, Anne P. Starling, Frances A. Tylavsky, Heather E. Volk, Tracey J. Woodruff, Yeyi Zhu, Deborah H. Bennett
Journal: Environmental Health Perspectives (2024)

Widespread exposure to organophosphate ester (OPE) flame retardants with potential reproductive toxicity raises concern regarding the impacts of gestational exposure on birth outcomes. Previous studies of prenatal OPE exposure and birth outcomes had limited sample sizes, with inconclusive results.
Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2
Authors: Kathrin Göritzer, Elisabetta Groppelli, Clemens Grünwald-Gruber, Rudolf Figl, Fengfeng Ni, Huimin Hu, Yuncheng Li, Yalan Liu, Qinxue Hu, Rama Devudu Puligedda, Jae-Wan Jung, Richard Strasser, Scott Dessain, Julian K.-C. Ma
Journal: Molecular Therapy (2024)

Passive delivery of antibodies to mucosal sites may be a valuable adjunct to COVID-19 vaccination to prevent infection, treat viral carriage, or block transmission. Neutralizing monoclonal IgG antibodies are already approved for systemic delivery, and several clinical trials have been reported for delivery to mucosal sites where SARS-CoV-2 resides and replicates in early infection. However, secretory IgA may be preferred because the polymeric complex is adapted for the harsh, unstable external mucosal environment. Here, we investigated the feasibility of producing neutralizing monoclonal IgA antibodies against SARS-CoV-2. We engineered two class-switched mAbs that express well as monomeric and secretory IgA (SIgA) variants with high antigen-binding affinities and increased stability in mucosal secretions compared to their IgG counterparts. SIgAs had stronger virus neutralization activities than IgG mAbs and were protective against SARS-CoV-2 infection in an in vivo murine model. Furthermore, SIgA1 can be aerosolized for topical delivery using a mesh nebulizer. Our findings provide a persuasive case for developing recombinant SIgAs for mucosal application as a new tool in the fight against COVID-19. Passive delivery of antibodies to mucosal sites may be a valuable adjunct to COVID-19 vaccination to prevent infection, treat viral carriage, or block transmission. Neutralizing monoclonal IgG antibodies are already approved for systemic delivery, and several clinical trials have been reported for delivery to mucosal sites where SARS-CoV-2 resides and replicates in early infection. However, secretory IgA may be preferred because the polymeric complex is adapted for the harsh, unstable external mucosal environment. Here, we investigated the feasibility of producing neutralizing monoclonal IgA antibodies against SARS-CoV-2. We engineered two class-switched mAbs that express well as monomeric and secretory IgA (SIgA) variants with high antigen-binding affinities and increased stability in mucosal secretions compared to their IgG counterparts. SIgAs had stronger virus neutralization activities than IgG mAbs and were protective against SARS-CoV-2 infection in an in vivo murine model. Furthermore, SIgA1 can be aerosolized for topical delivery using a mesh nebulizer. Our findings provide a persuasive case for developing recombinant SIgAs for mucosal application as a new tool in the fight against COVID-19.
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants
Authors: David J A Jenkins, Walter C Willett, Salim Yusuf, Frank B Hu, Andrea J Glenn, Simin Liu, Andrew Mente, Victoria Miller, Shrikant I Bangdiwala, Hertzel C Gerstein, Sabina Sieri, Pietro Ferrari, Alpa V Patel, Marjorie L McCullough, Loïc Le Marchand, Neal D Freedman, Erikka Loftfield, Rashmi Sinha, Xiao-Ou Shu, Mathilde Touvier, Norie Sawada, Shoichiro Tsugane, Piet A van den Brandt, Kerem Shuval, Tauseef Ahmad Khan, Melanie Paquette, Sandhya Sahye-Pudaruth, Darshna Patel, Teenie Fei Yi Siu, Korbua Srichaikul, Cyril W C Kendall, John L Sievenpiper, Bashyam Balachandran, Andreea Zurbau, Xunan Wang, Fred Liang, Wanning Yang
Journal: The Lancet Diabetes & Endocrinology (2024)
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review
Authors: Jamie Hartmann-Boyce, Patrick Highton, Karen Rees, Igho Onakpoya, Jana Suklan, Ffion Curtis, Lauren O'Mahoney, Elizabeth Morris, Laura Kudlek, Jessica Morgan, Rosie Lynch, Sanjana Marpadga, Samuel Seidu, Kamlesh Khunti
Journal: The Lancet Diabetes & Endocrinology (2024)